Figure 6.
![Schematic overview of [13C5,15N2]glutamine stable isotope tracings. (A) Tracing using [13C5,15N2]glutamine includes glutaminolytic and Krebs cycle pathways before (time 0) and 5 minutes after incubation with 1 µM fMLF. (B) Tracing using [13C5,15N2]glutamine in control and patient neutrophils before and after treatment with fMLF. The isotopologue intensities plotted correspond to labeling indicated in panel A (eg, 13C5,15N2 for Gln).](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/4/23/10.1182_bloodadvances.2020002225/3/advancesadv2020002225f6.png?Expires=1723410989&Signature=CiOuAKTXxqUbfWTOKrOdYGOzRfSjMeH1IrDBnDcmru8mROyU8jlK3Xf7tVKnQHDUNZdV6Ij1zv7E8OPuYqxbnaqDSy6Oegq86t99irnqFbKvW7Zr-iwIPvCWbmrigkosN9oDjwqA1XbNF3T1XB6tmaBz9-1LcnUdTtYe8BGRWGCqGEsYJpERukFyST9Cs0yK2kC98O474dfNbVadoOGfPOiDK30429IInFQf7Uk1cbx-aTd5DorPuMZJOfYvlLKzoBm8EuTig43tdV97EO9T~G9oKK-uPZ~KkXXKmZO~cl0BlGl1--jI2A1p2Vnxy6JQn4An48lv5pbbXKzQx9KC1g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Schematic overview of [13C5,15N2]glutamine stable isotope tracings. (A) Tracing using [13C5,15N2]glutamine includes glutaminolytic and Krebs cycle pathways before (time 0) and 5 minutes after incubation with 1 µM fMLF. (B) Tracing using [13C5,15N2]glutamine in control and patient neutrophils before and after treatment with fMLF. The isotopologue intensities plotted correspond to labeling indicated in panel A (eg, 13C5,15N2 for Gln).